← All trials
NCT04930900
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 4, 2021
- Primary completion
- Oct 3, 2021
- Completion date
- Oct 30, 2021
- First posted
- Jun 18, 2021
- Last posted
- Jul 26, 2021
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ARS Pharmaceuticals, Inc.Lead sponsor
- Northern Beach Clinical Research Pty Ltd,Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.